TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
The fireside chat is scheduled for Tuesday, December 2, 2025 at 12:30 PM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
In the Nov 28 session, TGTX declined 0.45%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Conference participation | Neutral | -0.5% | Announcement of Evercore Healthcare Conference fireside chat webcast availability. |
| Nov 19 | Recognition/award | Positive | -2.8% | Ranked #27 on Deloitte Technology Fast 500 driven by BRIUMVI growth. |
| Nov 10 | Conference participation | Neutral | +2.7% | TD Cowen Immunology & Inflammation Summit fireside chat and webcast access. |
| Nov 03 | Earnings and guidance | Positive | -3.1% | Q3 2025 results with strong BRIUMVI revenue, raised 2025 guidance and buybacks. |
| Oct 31 | Earnings call notice | Neutral | +2.2% | Scheduling of Q3 2025 results call and webcast with 30‑day replay. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative price reactions to clearly positive fundamental news (Fast 500 ranking, strong Q3 with raised guidance) while neutral conference or call announcements have sometimes coincided with modest gains.
Over the last few months, TG Therapeutics reported strong Q3 2025 results, with raised BRIUMVI revenue guidance and share repurchases on Nov 3, and later highlighted growth recognition by making Deloitte’s 2025 Technology Fast 500 list on Nov 19. Several conference and fireside chat announcements, including TD Cowen’s summit and today’s Evercore Healthcare Conference participation, focus on investor outreach via webcasts. Historically, clearly positive fundamentals have sometimes seen negative next‑day moves, while neutral outreach events have produced mixed but occasionally positive reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
